{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:40:08Z","timestamp":1793284808908,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023181","name":"Agencja Bada\u0144 Medycznych","doi-asserted-by":"publisher","award":["BPN\/WAL\/2023\/1\/00016"],"award-info":[{"award-number":["BPN\/WAL\/2023\/1\/00016"]}],"id":[{"id":"10.13039\/501100023181","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023181","name":"Agencja Bada\u0144 Medycznych","doi-asserted-by":"publisher","award":["BPN\/WAL\/2023\/1\/00061"],"award-info":[{"award-number":["BPN\/WAL\/2023\/1\/00061"]}],"id":[{"id":"10.13039\/501100023181","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014434","name":"Narodowa Agencja Wymiany Akademickiej","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003083","name":"European Association of Urology","doi-asserted-by":"publisher","award":["S-2023-0006"],"award-info":[{"award-number":["S-2023-0006"]}],"id":[{"id":"10.13039\/501100003083","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","award":["K120706"],"award-info":[{"award-number":["K120706"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.euf.2025.05.006","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T23:38:44Z","timestamp":1747870724000},"page":"109-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Androgen Receptor Pathway Inhibitor Monotherapy in Prostate Cancer: Safety, Oncologic Outcomes, and Quality of Life\u2014A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"12","author":[{"given":"Tam\u00e1s","family":"Fazekas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Miszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Giesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"K\u00f3i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Zattoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Rodriguez-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tibor","family":"Szarvas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Kryst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan G\u00f3mez","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel S.","family":"Merseburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria De","family":"Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Joniau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Nyir\u00e1dy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Gandaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Rajwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2025.05.006_b0005","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II\u20142024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.05.006_b0010","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/jamaoncol.2024.0591","article-title":"Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: a review","volume":"10","author":"Hussain","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euf.2025.05.006_b0015","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/jamaoncol.2024.1549","article-title":"Cardiovascular events and androgen receptor signaling inhibitors in advanced prostate cancer: a systematic review and meta-analysis","volume":"10","author":"El-Taji","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euf.2025.05.006_b0020","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1002\/cncr.24283","article-title":"Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer","volume":"115","author":"Taylor","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2025.05.006_b0025","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1677\/erc.0.0060315","article-title":"Aromatase and gynecomastia","volume":"6","author":"Braunstein","year":"1999","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.euf.2025.05.006_b0030","first-page":"2266","article-title":"Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen","volume":"83","author":"Khosla","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.euf.2025.05.006_b0035","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.05.006_b0040","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2025.05.006_b0045","unstructured":"Higgins JPT, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). Cochrane; 2022."},{"key":"10.1016\/j.euf.2025.05.006_b0050","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/XEB.0000000000000054","article-title":"Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data","volume":"13","author":"Munn","year":"2015","journal-title":"Int J Evid Based Healthc"},{"key":"10.1016\/j.euf.2025.05.006_b0055","unstructured":"U.S. Department of Health and Human Services NIH, National Cancer Institute. Common terminology criteria for adverse events (CTCAE). https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"key":"10.1016\/j.euf.2025.05.006_b0060","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/XEB.0000000000000065","article-title":"Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness","volume":"13","author":"Tufanaru","year":"2015","journal-title":"Int J Evid Based Healthc"},{"key":"10.1016\/j.euf.2025.05.006_b0065","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1002\/sim.4040","article-title":"Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data","volume":"29","author":"Stijnen","year":"2010","journal-title":"Stat Med"},{"key":"10.1016\/j.euf.2025.05.006_b0070","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2025.05.006_b0075","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2025.05.006_b0080","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.ijrobp.2021.02.027","article-title":"Enzalutamide with radiation therapy for intermediate-risk prostate cancer: a phase 2 study","volume":"110","author":"Kaplan","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euf.2025.05.006_b0085","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.891886","article-title":"Phase II study of enzalutamide combined with hypofractionated radiation therapy (ENZART) for localized intermediate risk prostate cancer","volume":"12","author":"Lara","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.euf.2025.05.006_b0090","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41391-022-00496-8","article-title":"NEAR trial: a single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer","volume":"25","author":"Lee","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euf.2025.05.006_b0095","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/iju.14994","article-title":"Patient-reported outcomes of a phase II neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate- to high-risk prostate cancer (NEAR) trial","volume":"29","author":"Yang","year":"2022","journal-title":"Int J Urol"},{"key":"10.1016\/j.euf.2025.05.006_b0100","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S1470-2045(14)70129-9","article-title":"Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study","volume":"15","author":"Tombal","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2025.05.006_b0105","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.eururo.2015.01.027","article-title":"Long-term efficacy and safety of enzalutamide monotherapy in hormone-na\u00efve prostate cancer: 1- and 2-year open-label follow-up results","volume":"68","author":"Tombal","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.05.006_b0110","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.juro.2017.08.103","article-title":"Long-term antitumor activity and safety of enzalutamide monotherapy in hormone na\u00efve prostate cancer: 3-year open label followup results","volume":"199","author":"Tombal","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.05.006_b0115","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/JU.0000000000003038","article-title":"Pathological effects of apalutamide in lower-risk prostate cancer: results from a phase II clinical trial","volume":"209","author":"Schweizer","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.05.006_b0120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.euros.2022.01.007","article-title":"A feasibility study of the therapeutic response and durability of short-term androgen-targeted therapy in early prostate cancer managed with surveillance: the therapeutics in active prostate surveillance (TAPS01) study","volume":"38","author":"Barrett","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euf.2025.05.006_b0125","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/bju.16414","article-title":"A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates","volume":"134","author":"Hahn","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2025.05.006_b0130","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/5454727","article-title":"Randomized, open-label phase 2 study of apalutamide plus androgen deprivation therapy versus apalutamide monotherapy versus androgen deprivation monotherapy in patients with biochemically recurrent prostate cancer","volume":"2022","author":"Aggarwal","year":"2022","journal-title":"Prostate Cancer"},{"key":"10.1016\/j.euf.2025.05.006_b0135","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.euros.2021.09.015","article-title":"Randomized phase 2 trial of abiraterone acetate plus prednisone, degarelix, or the combination in men with biochemically recurrent prostate cancer after radical prostatectomy","volume":"34","author":"Autio","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euf.2025.05.006_b0140","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.euo.2024.01.009","article-title":"A phase 2 randomized open-label study of oral darolutamide monotherapy versus androgen deprivation therapy in men with hormone-sensitive prostate cancer (EORTC-GUCG 1532)","volume":"7","author":"Tombal","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2025.05.006_b0145","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1200\/JCO.22.01662","article-title":"Phase II randomized study of salvage radiation therapy plus enzalutamide or placebo for high-risk prostate-specific antigen recurrent prostate cancer after radical prostatectomy: the SALV-ENZA trial","volume":"41","author":"Tran","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.05.006_b0150","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1158\/1078-0432.CCR-16-1357","article-title":"Neoadjuvant enzalutamide prior to prostatectomy","volume":"23","author":"Montgomery","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2025.05.006_b0155","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001556","article-title":"Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer","volume":"9","author":"Madan","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.euf.2025.05.006_b0160","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejca.2021.08.032","article-title":"A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415)","volume":"158","author":"Maluf","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euf.2025.05.006_b0165","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamaoncol.2022.1641","article-title":"Enzalutamide monotherapy vs active surveillance in patients with low-risk or intermediate-risk localized prostate cancer: the ENACT randomized clinical trial","volume":"8","author":"Shore","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euf.2025.05.006_b0170","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41391-022-00533-6","article-title":"LHRH sparing therapy in patients with chemotherapy-na\u00efve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial","volume":"25","author":"Ohlmann","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euf.2025.05.006_b0175","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300251","article-title":"Enzalutamide and quality of life in biochemically recurrent prostate cancer","volume":"2","author":"Freedland","year":"2023","journal-title":"NEJM Evid"},{"issue":"5","key":"10.1016\/j.euf.2025.05.006_b0180","doi-asserted-by":"crossref","first-page":"5080","DOI":"10.1200\/JCO.2019.37.15_suppl.5080","article-title":"Evaluation of the patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) with abiraterone acetate plus prednisone (AAP), degarelix (D), or the combination in men with biochemically recurrent prostate cancer (BCRPC)","volume":"37","author":"Autio","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.05.006_b0185","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/jamaoncol.2023.0998","article-title":"Association of second-generation antiandrogens with cognitive and functional toxic effects in randomized clinical trials: a systematic review and meta-analysis","volume":"9","author":"Nowakowska","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euf.2025.05.006_b0190","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.eururo.2023.06.012","article-title":"Clinical characterization of patients diagnosed with prostate cancer and undergoing conservative management: a PIONEER analysis based on big data","volume":"85","author":"Gandaglia","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.05.006_b0195","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41585-024-00925-4","article-title":"PIONEER big data platform for prostate cancer: lessons for advancing future real-world evidence research","volume":"22","author":"Lawlor","year":"2025","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euf.2025.05.006_b0200","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.euf.2024.06.008","article-title":"Is there a place for de-escalating therapy in patients with metastatic hormone-sensitive prostate cancer?","volume":"10","author":"Turco","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2025.05.006_b0205","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.euo.2023.01.001","article-title":"Adverse events and androgen receptor signaling inhibitors in the treatment of prostate cancer: a systematic review and multivariate network meta-analysis","volume":"6","author":"Cao","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2025.05.006_b0210","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1530\/EJE-22-0318","article-title":"Effects of oestradiol treatment on hot flushes in men undergoing androgen deprivation therapy for prostate cancer: a randomised placebo-controlled trial","volume":"187","author":"Russell","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.euf.2025.05.006_b0215","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(09)70338-9","article-title":"Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial","volume":"11","author":"Irani","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2025.05.006_b0220","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.euros.2022.09.006","article-title":"Estetrol prevents hot flushes and improves quality of life in patients with advanced prostate cancer treated with androgen deprivation therapy: the PCombi study","volume":"45","author":"Zimmerman","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euf.2025.05.006_b0225","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.clgc.2013.05.004","article-title":"Luteinizing hormone-releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects","volume":"11","author":"Walker","year":"2013","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euf.2025.05.006_b0230","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.eururo.2009.05.019","article-title":"An open, randomised, multicentre, phase 3 trial comparing the efficacy of two tamoxifen schedules in preventing gynaecomastia induced by bicalutamide monotherapy in prostate cancer patients","volume":"57","author":"Bedognetti","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.05.006_b0235","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1470-2045(05)70103-0","article-title":"Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial","volume":"6","author":"Perdon\u00e0","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2025.05.006_b0240","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ijrobp.2004.03.022","article-title":"Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia","volume":"60","author":"Tyrrell","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euf.2025.05.006_b0245","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00066-020-01598-9","article-title":"Treatment strategies to prevent and reduce gynecomastia and\/or breast pain caused by antiandrogen therapy for prostate cancer : Statement from the DEGRO working group prostate cancer","volume":"196","author":"Ghadjar","year":"2020","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.euf.2025.05.006_b0250","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.euo.2023.10.010","article-title":"Nonsurgical interventions to prevent disease progression in prostate cancer patients on active surveillance: a systematic review and meta-analysis","volume":"7","author":"Matsukawa","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2025.05.006_b0255","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.3390\/cancers16132331","article-title":"Is there an opportunity to de-escalate treatments in selected patients with metastatic hormone-sensitive prostate cancer?","volume":"16","author":"G\u00f3mez-Aparicio","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.euf.2025.05.006_b0260","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.euo.2024.04.004","article-title":"The state of intermediate clinical endpoints as surrogates for overall survival in prostate cancer in 2024","volume":"7","author":"Miszczyk","year":"2024","journal-title":"Eur Urol Oncol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240545692500118X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240545692500118X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:59:09Z","timestamp":1770145149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240545692500118X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S240545692500118X"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2025.05.006","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Androgen Receptor Pathway Inhibitor Monotherapy in Prostate Cancer: Safety, Oncologic Outcomes, and Quality of Life\u2014A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2025.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}